Sertraline decreases serum level of interleukin-6 (IL-6) in hemodialysis patients with depression: Results of a randomized double-blind, placebo-controlled clinical trial

Taraz, Mohammad; Khatami, Mohammad Reza; Dashti‐Khavidaki, Simin; Akhonzadeh, Shahin; Noorbala, Ahmad-Ali; Ghaeli, Padideh; Taraz, Saeideh

doi:10.1016/j.intimp.2013.09.020

Cited by 70 publications

(76 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These self-reported questionnaires have been previous validated and use a cut-off point of ≥16 and ≥10 for the diagnosis of depressive symptoms [13,14]. Whereas previous studies using these and other screening questionnaires have variously reported a positive association between depression and increased CRP [8,9], or found no association [10,11].…”

Section: Discussionmentioning

confidence: 99%

“…Depression scores were similar in those with normal and high CRP (BDI-II (9(5-17) vs 11 (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)) or PHQ (4(2-9) vs 6(2-10)). In adjusted multivariable regression BDI-II scores were associated with previous history of depression (β 10.8, p<0.001), serum albumin (β 0.41, p<0.001), anuria (β 2.4, p<0.037), diabetes (β 2.7, p=0.033) and age (β -0.10, p=0.009).…”

Section: Crp (>5 Mg/l)mentioning

confidence: 91%

See 1 more Smart Citation

C reactive protein and depressive symptoms in hemodialysis patients: A questionable association

Chilcot

Friedli

Guirguis

et al. 2016

Hemodialysis International

View full text Add to dashboard Cite

Introduction: Patients with advanced chronic kidney disease (CKD) on haemodialysis (HD) may have increased C reactive protein (CRP) values and depressive symptoms. There is debate about the strength and nature of previously reported associations. We investigated these issues in a cohort of patients on HD. Methods: We screened for depressive symptoms using two valadiated depression screening tools: the Beck Depression Inventory‐II (BDI‐II), Patient Health Questionnaire (PHQ‐9). Demographic and clinical correlates of depression symptoms were eveluated in adjusted linear and logistic regression models, which included extra renal comorbidity and high CRP (>5 mg/L). Findings: Three hundred and ninety‐six HD patients were studied; 63.1% male, mean age 63.1 ± 16.4 years, median CRP 6 (5–15) mg/L. Depression scores were similar in those with normal and high CRP (BDI‐II (9(5–17) vs. 11(6–20)) or PHQ (4(2–9) vs. 6(2–10)). In adjusted multivariable regression BDI‐II scores were associated with previous history of depression (β 10.8, P < 0.001), serum albumin (β 0.41, P < 0.001), anuria (β 2.4, P < 0.037), diabetes (β 2.7, P = 0.033), and age (β −0.10, P = 0.009). High CRP was not independently associated with BDI‐II (β 2.20, P = 0.057), though was with PHQ‐9 (β 1.20, P = 0.046). In logistic regression those with high CRP were 1.9 times more likely to score ≥16 on BDI‐II screening (P = 0.016), but did not relate significantly to a PHQ‐score ≥10. Discussion: A relationship was observed between CRP and depression symptoms, though the effect was small, of unlikely clinical significance, and inconsistent between depression measures. Previous reports of this association may reflect overlap between symptoms of depression and advanced CKD.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Crp (>5 Mg/l)mentioning

confidence: 91%

C reactive protein and depressive symptoms in hemodialysis patients: A questionable association

Chilcot

Friedli

Guirguis

et al. 2016

Hemodialysis International

View full text Add to dashboard Cite

show abstract

Section: Treat Inflammation In Depressionmentioning

confidence: 99%

“…In a randomized, double-blind, placebo-controlled trial sertraline significantly decreased serum level of interleukin-6 [104]. The anti-inflammatory effect of sertraline was independent to its efficacy for depression treatment [104]. Imipramine down-regulates microglial activation, attenuates stress-induced corticosterone and interleukin-6 responses in plasma, decreases the percentage of monocytes and granulocytes in the bone marrow and circulation and abrogates the accumulation of macrophages in the brain [105].…”

Section: Treat Inflammation In Depressionmentioning

confidence: 99%

Depression in the Context of Medical Disorders: New Pharmacological Pathways Revisited

Lang¹,

Walter²

2017

Neurosignals

View full text Add to dashboard Cite

The depressive state has been characterised as one of elevated inflammation, changed cardiovascular parameters and a deranged metabolic situation all of which holds promise for a better understanding and handling of treatment-resistance in affective disorders as well as for future developments in treatment algorithms. In this context several biomarkers are differentially regulated by antidepressant treatment and connected to metabolic, inflammatory, cardiovascular and apoptotic components of the pathophysiology, i.e. adiponectin, apolipoprotein-B, B-type natriuretic peptide, cortisol, CRP, cysteine, homocysteine, fibrinogen, adiponectin, BMI, glycated hemoglobin A1c, leptin, interferon-gamma, high-density lipoprotein, interleukin interleukin-1alpha, -1beta, -2, -4, -5, -6, -8, -10, -12, -13, -17, insulin-like growth factor-1, low-density lipoprotein, myeloperoxidase, osteoprotegerin, tumour necrosis factor alpha, troponins, triglycerides etc. In this context antidepressants exert different modulatory effects on the outcome, incidence and mortality concerning several severe disorders, i.e. cancer, diabetes, stroke, inflammation, stroke and cardiovascular risk. Vice versa different drugs used in the treatment of these disorders have a favourable effect in depressive states, e.g. statins, aspirine, NSAIDs, pioglitazone, celecoxib, peroxisome proliferator-activated receptor-gamma agonists and minocycline. In this review, actions of different antidepressant treatment strategies on cancer, stroke, diabetes and cardiovascular disorders are shown and the influence on the outcome of the disorders is differentially discussed. In conclusion a hypothetic model for the implication of actual findings in everyday clinical practice is proposed. In this context personalized treatment could be used to tailor treatment to specific individuals according to their clinical endophenotypes. Moreover a potential target for the development of novel intervention strategies might be used.

show abstract

“…The capacity of cytokines, such as IL6, TNF-a and INF-ү to sustain ineffective haematopoiesis suggests that intervention in this pathway could provide benefit. Similar to LR-MDS, deregulated cytokine signalling is observed in both depression and rheumatoid arthritis and selective serotonin reuptake inhibitors (SSRIs) abrogate the symptoms of these disorders in part by modulating cytokine abnormalities (Sutcigil et al, 2007;Baharav et al, 2012;Taraz et al, 2013). We hypothesized that SSRIs could delay disease progression and prolong survival in LR-MDS patients.…”

mentioning

confidence: 99%

Significant improvement in overall survival among patients diagnosed with low‐risk myelodysplastic syndrome treated with selective serotonin reuptake inhibitors

Yellapragada

Mims

et al. 2016

Br J Haematol

View full text Add to dashboard Cite

Sertraline decreases serum level of interleukin-6 (IL-6) in hemodialysis patients with depression: Results of a randomized double-blind, placebo-controlled clinical trial

Cited by 70 publications

References 45 publications

C reactive protein and depressive symptoms in hemodialysis patients: A questionable association

C reactive protein and depressive symptoms in hemodialysis patients: A questionable association

Depression in the Context of Medical Disorders: New Pharmacological Pathways Revisited

Significant improvement in overall survival among patients diagnosed with low‐risk myelodysplastic syndrome treated with selective serotonin reuptake inhibitors

Contact Info

Product

Resources

About